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To evaluate multidrug-resistant strains of Salmonella
enterica serotype Typhimurium, including definitive type
104 (DT104) in the United States, we reviewed data from
the National Antimicrobial Resistance Monitoring System
(NARMS). In 1997 to 1998, 703 (25%) of 2,767 serotyped
Salmonella isolates received at NARMS were S.
Typhimurium; antimicrobial susceptibility testing and phage
typing were completed for 697. Fifty-eight percent (402)
were resistant to >1 antimicrobial agent. Three multidrug-
resistant (>5 drugs) strains accounted for (74%) 296 of all
resistant isolates. Ceftriaxone resistance was present in 8
(3%), and nalidixic acid resistance in 4 (1%), of these mul-
tidrug-resistant strains. By phage typing, 259 (37%) of S.
Typhimurium isolates were DT104, 209 (30%) were of
undefined type and 103 (15%) were untypable. Fifty per-
cent (202) of resistant (>1 drug) isolates were DT104.
Multidrug-resistant  S.  Typhimurium isolates, particularly
DT104, account for a substantial proportion of S.
Typhimurium isolates; ceftriaxone resistance is exhibited by
some of these strains. 
S
almonella enterica serotype Typhimurium is the most
common  Salmonella  serotype in the United States,
accounting for 29% of the approximately 30,000 laborato-
ry-confirmed Salmonella infections reported annually to
the Centers for Disease Control and Prevention (CDC)
from 1968 to 1998 (1). Among Salmonella serotypes,
Typhimurium exhibits one of the highest prevalences of
antimicrobial resistance (2,3). Of particular concern is a
multidrug-resistant strain of S. Typhimurium defined by
phage typing as definitive type 104 (DT104). Multidrug-
resistant DT104 was first detected in the United Kingdom
in 1984 and was first isolated in the United States in 1985
(4,5). In addition to the phage reactions, this strain is char-
acterized by its multiple antimicrobial-resistance pattern to
ampicillin, chloramphenicol, streptomycin, sulfamethoxa-
zole, and tetracycline (R-type ACSSuT). The number of
reported human isolates of DT104 R-type ACSSuT in the
United Kingdom increased from 259 isolates in 1990 to
4,006 isolates in 1996 (6). 
In the United States, antimicrobial susceptibility testing
determined that the proportion of S. Typhimurium isolates
that were R-type ACSSuT increased from <1% in 1980 to
34% in 1996 (7). Although phage typing of S. Typhi-
murium isolates is not routinely done in the United States,
93% of the R-type ACSSuT isolates tested from a national
sample of isolates from all state and public health labora-
tories conducted in 1995 were DT104, which suggests that
9% of all human Salmonella infections in this country in
1995 were caused by S. Typhimurium DT104 R-type
ACSSuT (5,7). 
The objectives of this analysis were to determine the
antimicrobial-resistance patterns seen among S.
Typhimurium isolates received at CDC through the
National Antimicrobial Resistance Monitoring System
(NARMS) from 1997 through 1998 and describe the distri-
bution of phage types, including DT104, among S.
Typhimurium isolates with the most common resistance
patterns. 
Methods 
In 1996, NARMS was established to prospectively
monitor the patterns of antimicrobial-drug resistance
among human enteric pathogens, including nontyphoidal
Salmonella isolates received at select public health labora-
tories in the United States (8). NARMS began as collabo-
ration between CDC, the U.S. Food and Drug
Administration Center for Veterinary Medicine, and 12
state health departments (California, Colorado,
Connecticut, Florida, Georgia, Kansas, Massachusetts,
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Virginia) and two local health departments (Los Angeles
County and New York City). Two additional state health
departments (Maryland and New York) joined NARMS in
1997. According to 1998 U.S. postcensus estimates (avail-
able from http://www.census.gov/population/estimates/
state), the population served by these 16 state and local
health departments was approximately 97 million persons,
37% of the U.S. population. 
From 1997 through 1998, NARMS-participating public
health laboratories forwarded every 10th nontyphoidal
Salmonella isolate serotyped at their laboratory to CDC for
susceptibility testing. At CDC, partial range MICs were
determined by using broth microdilution (Sensititre, Trek
Diagnostics, Westlake, OH) for 16 antimicrobial agents:
amikacin, amoxicillin-clavulanic acid (Cl), ampicillin (A),
apramycin (Ap), ceftiofur (a third-generation cephalosporin
used in veterinary medicine) (Cef), ceftriaxone (Cx),
cephalothin (Cep), chloramphenicol (C), ciprofloxacin,
gentamicin (G), kanamycin (K), nalidixic acid (N), strepto-
mycin (S), sulfamethoxazole (Su), tetracycline (T), and
trimethoprim-sulfamethoxazole (Tm) (NARMS 1997, 1998
Annual Reports; available from http://www.cdc.gov/
narms). National Committee for Clinical Laboratory
Standards (NCCLS) interpretive criteria were used when
available (9); resistance to ceftiofur, apramycin, and strep-
tomycin was defined as an MIC >8 µg/mL, >32 µg/mL, and
>64 µg/mL, respectively. Isolates that exhibited decreased
susceptibility to third-generation cephalosporins (ceftiofur
or ceftriaxone) were confirmed as Salmonella and tested for
the full range of MICs for ceftriaxone by broth microdilu-
tion using NCCLS standards and by further molecular char-
acterization (10,11). All isolates with intermediate
susceptibilities were categorized as susceptible for this
analysis with the understanding that an intermediate suscep-
tibility to some drugs, in particular, ceftriaxone, would
remove this drug as a clinical option. 
Phage types were determined by using a scheme of 31
S. Typhimurium typing phages based on the method of
Anderson et al. (12) and the interpretive guide supplied by
the Public Health Laboratory Service (PHLS) in Colindale,
United Kingdom. At the time this set of S. Typhimurium
isolates was tested, additional S. Typhimurium typing
phages 1, 2, 3, and 18 (which would have enabled designa-
tion of definitive types 193, 194, 195, and 208) were not
used. S. Typhimurium isolates phage typed as definitive
type 104, 104a, 104b, 104c, or U302 (closely related defin-
itive types) were classified together as DT104 complex
(hereafter referred to as DT104). Those S. Typhimurium
isolates that reacted to phages but did not conform to any
defined pattern were classified as RDNC (reacts but does
not conform), and those that did not react with any of the
typing phages used at the time were classified as unty-
pable. Isolates that did not have antimicrobial susceptibili-
ty test results or phage type results were excluded from
analysis. Invasive isolates were classified as those isolated
from specimens collected from normally sterile sites, such
as blood or cerebral spinal fluid; enteric isolates were those
isolated from stool specimens or rectal swabs. Isolates
from specimens collected from other (e.g., urine) or
unknown sources were excluded from analysis by speci-
men source. Statistical analysis was performed with Epi
Info 6.04 (CDC, Atlanta, GA) and SAS 6.12 software
(SAS Institute Inc., Cary, NC). Statistical testing of differ-
ences in proportions was conducted using the chi-square
test; p values <0.05 were considered significant. 
Results 
Resistance Testing 
A total of 2,767 serotyped nontyphoidal Salmonella
isolates were received at CDC through NARMS from 1997
through 1998; 1,301 in 1997 and 1,466 in 1998. Of these,
703 (25%) were Salmonella serotype Typhimurium
(including serotype Typhimurium var. Copenhagen); 326
(25%) in 1997 and 377 (26%) in 1998. Antimicrobial sus-
ceptibility testing and phage typing was completed on 697
isolates. 
The antimicrobial agents to which S. Typhimurium iso-
lates demonstrated the highest level of resistance were sul-
famethoxazole (53%), streptomycin (51%), tetracycline
(50%), ampicillin (48%), chloramphenicol (35%),
kanamycin (16%), amoxicillin-clavulanic acid (5%),
cephalothin (5%), gentamicin (4%), trimethoprim-sul-
famethoxazole (4%), ceftiofur (2%), ceftriaxone (1%), and
nalidixic acid (1%). No isolates were resistant to amikacin,
apramycin, or ciprofloxacin. 
Overall, 402 (58%) S. Typhimurium isolates were
resistant to >1 antimicrobial agent tested, 379 (54%) were
resistant to >2 antimicrobial agents, and 312 (45%) were
resistant to >5 antimicrobial agents (Table 1). Three dis-
tinct multidrug-resistant patterns were found among the
312 isolates resistant to >5 agents: 209 (67%) were resist-
ant to ampicillin, chloramphenicol, streptomycin, sul-
famethoxazole and tetracycline (R-type ACSSuT), 26
(8%) were additionally resistant to kanamycin (R-type
ACKSSuT) and 61 (20%) were resistant to ampicillin,
kanamycin, streptomycin, sulfamethoxazole, and tetracy-
cline (R-type AKSSuT). 
The proportion of S. Typhimurium isolates that were R-
type ACSSuT, R-type ACKSSuT, or R-type AKSSuT var-
ied among the 16 NARMS sites. Among the 14 sites that
submitted >10 S. Typhimurium isolates, New York State
had the highest proportion of isolates that were one of these
phenotypes (64%), and Minnesota had the lowest (17%)
(p < 0.001) (Table 2). S. Typhimurium R-type ACSSuT was
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isolates that were R-type ACSSuT ranged from 4% in
Minnesota to 64% in New York State (Table 2). S.
Typhimurium R-type ACKSSuT isolates were not found in
California, New York State, Oregon, or West Virginia.
Salmonella  Typhimurium R-type AKSSuT isolates were
not found in New York State, Washington, or West Virginia,
and among other sites ranged from 4% in Maryland and
Colorado to 20% in Massachusetts (Table 2). 
Both R-type ACSSuT and R-type AKSSuT isolates
were identified in all months of the 2-year surveillance
period. In contrast, R-type ACKSSuT resistance was first
noted in isolates collected during June 1997; from this
point forward, R-type ACKSSuT isolates were found
every month. For each year, the proportion of S.
Typhimurium isolates that were R-type ACSSuT in the
winter (January–March) was 45% (61/135), compared
with 20% (41/201) in the summer (July–September) (p <
0.001).  
The proportion of multidrug-resistant isolates that were
R-type ACSSuT varied significantly by age (p < 0.01) for
the 542 isolates for which patient’s age was known. Those
from patients 40–49 years of age had the highest propor-
tion of R-type ACSSuT isolates (41%), and those 10–19
years of age had the lowest proportion (19%). 
R-type ACSSuT strains were significantly more likely
to be isolated from a sterile site (p < 0.01) than from stool
when compared with other R-types or with pansusceptible
S. Typhimurium isolates. Nine percent (19/203) of R-type
ACSSuT isolates were from blood compared with 3%
(9/291) of pansusceptible isolates. This association was
not seen with other R-types. 
Of the 209 S. Typhimurium R-type ACSSuT isolates,
15 (7%) were also resistant to amoxicillin-clavulanic acid,
4 (2%) were resistant to nalidixic acid, 3 (1%) were resist-
ant to cephalothin, 2 (1%) were resistant to trimethoprim,
2 (1%) were resistant to gentamicin, 1 was resistant to cef-
tiofur, and 1 was resistant to ceftriaxone. Of 26 S.
Multidrug-resistant Salmonella Typhimurium, United States
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Table 1. R-type and phage type distribution among Salmonella Typhimurium isolates, NARMS 1997–1998  
R-type
a  All isolates, N (%)  DT104, N (%)  RDNC
b, N (%)  Untypeable, N (%) 
ACSSuT  187 (27)  160 (62)  6 (3)  6 (6) 
ACSSuT+Cl  11 (1)  10 (4)  0  0 
ACSSuT+G  2 (<1)  2 (<1)  0  0 
ACSSuT+N  4 (<1)  4 (2)   0  0 
ACSSuT+Tm  1 (<1)  0   0  0 
ACSSuT+Cl+Cep  2 (<1)  1 (<1)  0  0 
ACSSuT+Cl+Tm  1 (<1)  1 (<1)  0  0 
ACSSuT+Cl+Cef+Cx+Cep  1 (<1)  1 (<1)  0  0 
ACSSuT total  209 (30)  179 (69)  6 (3)  6 (6) 
ACKSSuT  16 (2)  13 (5)  1 (<1)  2 (2) 
ACKSSuT+Cep+Tm  4 (<1)  0   0  4 (4) 
ACKSSuT+Cl+Cef+Cx+Cep  3 (<1)  0   0  3 (3) 
ACKSSuT+Cl+Cef+Cx+Cep+G  2 (<1)  1 (<1)  0  1 (1) 
ACKSSuT+Cl+Cef+Cx+Cep+G+Tm  1 (<1)  0   0  1 (1) 
ACKSSuT total  26 (4)  14 (5)  1 (<1)  11 (11) 
AKSSuT  51 (7)  5 (2)  8 (4)  34 (33) 
AKSSuT+Cep  4 (<1)  1 (<1)  1 (<1)  2 (2) 
AKSSuT+G  1 (<1)  0   1 (<1)  0 
AKSSuT+Cl+Cep  1 (<1)  0   0  0 
AKSSuT+Cep+G  2 (<1)  2 (<1)  0  0 
AKSSuT+Cl+Cep+G  1 (<1)  1 (<1)  0  0 
AKSSuT+Cef+Cx+Cep+N  1 (<1)  0  0  1 (1) 
AKSSuT total  61 (9)  9 (4)  10 (5)  37 (36) 
Pansusceptible  295 (42)  33 (13)  144 (69)  26 (25) 
Resistant to 1 antimicrobial agent  23 (3)  5 (2)  11 (5)  3 (3) 
Resistant to 2 antimicrobial agents  19 (3)  7 (3)  8 (4)  1 (1) 
Resistant to 3 antimicrobial agents  21 (3)  4 (2)  10 (5)  4 (4) 
Resistant to 4 antimicrobial agents  27 (4)  5 (2)  11 (5)  10 (10) 
Resistant to 5 antimicrobial agents  6 (<1)  3 (1)  2 (1)  1 (1) 
Resistant to 6 antimicrobial agents  4 (<1)  0   1 (<1)  0 
Resistant to 7 antimicrobial agents  5 (<1)  0   2 (1)  1 (1) 
Resistant to 9 antimicrobial agents  1 (<1)  0   0  1 (1) 
Total  697 (100)  259 (100)  209 (100)  104 (100) 
aNARMS, National Antimicrobial Resistance Monitoring System; Cl, amoxicillin-clavulanic acid; A, ampicillin; Ceft, ceftiofur;  Cx, ceftriaxone; Cep, cephalothin; C, 
chloramphenicol; G, .gentamicin; K, kanamycin; N, nalidixic acid;  S, streptomycin; Su, sulfamethoxazole;  T, tetracycline; Tm, trimethoprim-sulfamethoxazole.   
bReacts but does not conform. Typhimurium R-type ACKSSuT isolates, 10 (39%) were
resistant to cephalothin, 6 (23%) were resistant to amoxi-
cillin-clavulanic acid, 6 (23%) were resistant to ceftiofur,
6 (23%) were resistant to ceftriaxone, 5 (19%) were resist-
ant to trimethoprim, and 3 (12%) were resistant to gen-
tamicin. Of the 61 S. Typhimurium R-type AKSSuT
isolates, 9 (15%) were resistant to cephalothin, 4 (7%)
were resistant to gentamicin, 2 (3%) were resistant to
amoxicillin-clavulanic acid, 1 was resistant to ceftiofur, 1
was resistant to  ceftriaxone, and 1 was resistant to
nalidixic acid (Table 1). 
Although no S. Typhimurium isolates were resistant to
ciprofloxacin, two isolates had reduced susceptibility to
ciprofloxacin (both had MIC = 0.250 µg/mL), and both
isolates were R-type ACSSuT. Twelve S. Typhimurium
isolates had ceftriaxone MICs >32 µg/mL; 11 were resist-
ant (MIC >64 µg/mL). Nine (82%) of the 11 ceftriaxone
resistant isolates were from children <18 years of age; 7
were from children <6 years of age. As a group, these 11
isolates were among the most highly resistant seen, with 8
isolates (80%) resistant to >9 antimicrobial agents; 6 were
R-type ACKSSuT, 1 was R-type ACSSuT, and 1 was R-
type AKSSuT.  
Phage Testing 
Of the 697 S. Typhimurium phage typed, 259 (37%)
were DT104, 209 (30%) were RDNC, 103 (15%) were
untypable; 35 other phage types were identified at low fre-
quency (<3% of total) among the remaining 126 S.
Typhimurium isolates (Table 3). Among the 295 pansus-
ceptible S. Typhimurium isolates, there were 37 different
phage types; 144 (49%) were RDNC, 33 (11%) were
DT104, 26 (9%) were untypable, 20 (7%) were DT46, 14
(5%) were DT10, and 10 (3%) were DT2 isolates. Among
the 296 isolates that were R-type ACSSuT, ACKSSuT, or
AKSSuT, seven different phage types were found; 202
(68%) were DT104, 54 (18%) were untypable, 17 (6%)
were RDNC, 7 (2%) were DT12/12A, 6 (2%) were DT21,
6 (2%) were DT 110/110B, and 4 (1%) were DT120. All
three of these multidrug-resistant S. Typhimurium isolates
included some DT104 isolates; 179 (86%) of the 209
R-type ACSSuT isolates, 14 (54%) of the 26 R-type
ACKSSuT isolates, and 9 (15%) of the 61 R-type
AKSSuT isolates were DT104 (Figure). All four of the
nalidixic acid resistant R-type ACSSuT isolates were
DT104. Two other prevalent phage categories among mul-
tidrug-resistant S. Typhimurium isolates were RDNC (and
did not necessarily exhibit the same lysis pattern) and
untypable. Six (3%) of the R-type ACSSuT isolates, one
(4%) of the R-type ACKSSuT isolates, and 10 (3%) of the
R-type AKSSuT isolates were RDNC. Six (3%) of the R-
type ACSSuT isolates, 11 (42%) of the R-type ACKSSuT
isolates, and 37 (61%) of the R-type AKSSuT isolates
were untypable. Compared with other phage types,
DT104 isolates were more likely to be R-type ACSSuT
(86% vs. 3%; p < 0.01), and untypable isolates were more
likely to be R-type AKSSuT (61% vs. 16%; p < 0.01). 
Discussion 
This comprehensive study of phage type and antimicro-
bial resistance among S. Typhimurium isolates in the
United States confirms that multidrug resistance is common
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Table 2. Salmonella Typhimurium isolates with ACSSuT, ACKSSuT, or AKSSuT resistance patterns by site, NARMS 1997–1998  
Site  ACSSuT, N (%)  ACKSSuT, N (%)  AKSSuT, N (%)  Other R-types, N (%)  Pansusceptible, N (%)  Total N 
California
b  8 (32)  0  3 (12)  5 (20)  9 (36)  25 
Colorado  16 (36)  2 (4)  2 (4)  8 (18)  17 (38)  45 
Connecticut  15 (39)  1 (3)  4 (10)  6 (15)  13 (33)  39 
Florida  4 (45)  1 (11)  1 (11)  0  3 (33)  9 
Georgia  21 (26)  1 (1)  6 (8)  9 (11)  43 (54)  80 
Kansas  2 (11)  2 (11)  1 (5)  5 (26)  9 (47)  19 
Los Angeles
c  15 (25)  3 (5)  7 (12)  18 (31)  16 (27)  59 
Maryland  12 (44)  1 (4)  1 (4)  2 (7)  11 (41)  27 
Massachusetts  21 (24)  3 (3)  18 (21)  9 (10)  37 (42)  88 
Minnesota  2 (4)  2 (4)  5 (9)  12 (23)  32 (60)  53 
New Jersey  28 (32)  5 (6)  4 (5)  11 (13)  38 (44)  86 
New York City
d  10 (21)  2 (4)  7 (15)  7 (15)  22 (45)  48 
New York State
e  21 (64)  0  0  2 (6)  10 (30)  33 
Oregon  8 (30)  0  2 (7)  2 (7)  15 (56)  27 
Washington  25 (48)  3 (6)  0  7 (13)  17 (33)  52 
West Virginia  1 (14)  0  0  3 (43)  3 (43)  7 
Total  209 (30)  26 (4)  61 (9)  106 (15)  295 (42)  697 
aNARMS, National Antimicrobial Resistance Monitoring System. 
bSan Francisco and Alameda Counties. 
cLos Angeles County. 
dFive counties of New York City (Bronx, Kings, New York, Queens, Richmond). 
eExcluding New York City. among S. Typhimurium isolates and that DT104 is the dom-
inant phage type. We found that 42% of S. Typhimurium
collected during 1997–1998 belonged to one of three mul-
tidrug-resistant phenotypes: R-type ACSSuT, R-type
ACKSSuT, and R-type AKSSuT. Overall, 68% of these iso-
lates belonging to one of the multidrug-resistant pheno-
types were DT104, with the greatest proportion of DT104
among the R-type ACSSuT isolates (86%); taken together,
28% of all S. Typhimurium isolates were DT104 R-type
ACSSuT. Since an estimated 1.4 million persons are infect-
ed with Salmonella each year in the United States (13),
these data suggest that approximately 100,000 persons
were infected annually with S. Typhimurium DT104 R-type
ACSSuT in 1997 and 1998 in this country. 
This study also contributes to our understanding of the
descriptive epidemiology of S. Typhimurium R-type
ACSSuT. S. Typhimurium R-type ACSSuT isolates were
found in all sites with the highest proportion from New
York and the lowest from Minnesota. The proportion of S.
Typhimurium isolates that were R-type ACSSuT increased
during the winter and declined during the summer. S.
Typhimurium R-type ACSSuT isolates were also most
likely to be found in persons 40–49 years of age and least
likely to be from those 10–19 years of age. S.
Typhimurium R-type ACSSuT isolates were more likely to
be isolated from sterile sites than were other multidrug-
resistant or susceptible S. Typhimurium isolates. Further
studies are needed to determine if S. Typhimurium R-type
ACSSuT isolates are more invasive than other S.
Typhimurium isolates. 
The other two predominant multidrug-resistant S.
Typhimurium seen were R-type ACKSSuT and AKSSuT.
Those isolates were largely RDNC or untypable by phage
typing. At the time phage typing was done, additional typ-
ing phages 1, 2, 3 and 18 of the Colindale scheme were not
used. These additional typing phages assist in defining
what would otherwise be interpreted as untypable. The
untypable categories described here could include isolates
that would now be designated as DT193, 194, 195, or 208
if these additional typing phages were applied. Multidrug
resistance has been described among DT193 and 208 iso-
lates identified in other studies (14,15). DT193 and 208
represented 10.9% of the pentaresistant S. Typhimurium
from animals submitted to the U. S. National Veterinary
Services Laboratory in 1998 (15), and DT193 was also the
most prevalent phage type among 155 multidrug-resistant
S. Typhimurium tested in southern Italy between 1992 and
1997 (16). 
The number of phage-untypable isolates within
ACKSSuT and AKSSuT resistance patterns raises the
Multidrug-resistant Salmonella Typhimurium, United States
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Table 3. Salmonella Typhimurium isolates by phage type,  
1997–1998 
Phage type  N (%) 
104  168 (24) 
104A  24 (3) 
104B  27 (4) 
104C  4 (1) 
U302  36 (5) 
DT104   259 (37) 
RDNC  209 (30) 
Untypeable  103 (15) 
1  6 (1) 
2  14 (2) 
4A  1 (<1) 
9  1 (<1) 
10  14 (2) 
12/12A  10 (1) 
21  6 (1) 
22  2 (<1) 
18  1 (<1) 
36  1 (<1) 
38  1 (<1) 
40/40 VAR  3 (<1) 
41/41A  3 (<1) 
46  20 (3) 
66  2 (<1) 
69  2 (<1) 
87  1 (<1) 
105  1 (<1) 
106  3 (<) 
107  1 (<1) 
110/110B  10 (2) 
114  1 (<1) 
120  6 (1) 
124  2 (<1) 
126  5 (<1) 
156  3 (<1) 
160  2 (<1) 
164  1 (<1) 
167  1 (<1) 
170  1 (<1) 
U291  1 (<1) 
Total  697 (100) 
 
Figure. Distribution of Salmonella Typhimurium phage types
among resistance patterns.question of whether multidrug resistance is associated with
untypability. Within R-type ACKSSuT, 42% of isolates
were untypable and within R-type AKSSuT, 61% were
untypable. Transformation of Salmonella enterica serotype
Enteritidis (S. Enteritidis) with drug resistance plasmids
has been documented to cause changes in phage type
(17,18). Brown et al. (17) showed a shift of PT8 to 13a
upon acquisition of IncX plasmid pOG670, which confers
resistance to ampicillin and kanamycin. Threlfall et al. (18)
reduced susceptibility to phages within the S. Enteritidis
typing set in several S. Enteritidis isolates, and in two cases
produced untypable isolates by transforming isolates with
an IncN plasmid that contained ampicillin and strepto-
mycin resistance factors. Further work to explore the plas-
mid and prophage content of isolates from each resistance
type, may clarify the importance of these extrachromoso-
mal elements in determinating resistance and phage type. 
The emergence of clinically important antimicrobial
resistance is cause for concern. Occurrence of third-gener-
ation cephalosporin resistance among the multidrug-resist-
ant subpopulation of S. Typhimurium isolates is notable.
Third-generation cephalosporins (e.g., ceftriaxone) are
important in treating invasive Salmonella infections, par-
ticularly in children (19). In fact, most isolates we describe
with ceftriaxone resistance came from children <18 years
of age. A plasmid-mediated blaCMY-2 mechanism has
been described as the source for the expanded-spectrum β-
lactam resistance among Salmonella that includes ceftriax-
one seen in recent years in the United States (10). The
prevalence of blaCMY-2 has continued to increase among
multidrug-resistant  Salmonella, especially serotype
Newport, in more recent years (20,21). Occurrence of
nalidixic acid resistance among multidrug-resistant S.
Typhimurium R-type ACSSuT DT104 is also notable.
Fluoroquinolones are also important in treating invasive
Salmonella infections, particularly in adults. Although no
fluoroquinolone resistant isolates were identified in this
study, four R-type ACSSuT isolates were resistant to
nalidixic acid; patients with nalidixic acid resistant
Salmonella DT104 R-type ACSSuT infections have failed
treatment with fluoroquinolones (19). 
Resistance to multiple antimicrobial agents is common
among S. Typhimurium. With continued selective pressure
that is created by antimicrobial drug use in humans, agri-
culture, and particularly food animals, we can expect to see
a continued high prevalence of multidrug resistance
among S. Typhimurium. Identification and subtyping of S.
Typhimurium isolates is essential for understanding and
controlling multidrug-resistant S. Typhimurium infections.
Phage typing provides a useful, although resource-inten-
sive, subtyping tool for this common serotype, although
isolates that are RDNC and untypeable need to be catego-
rized into groups that reflect the circulating S.
Typhimurium strains found in the United States.
Continued surveillance of antimicrobial resistance and
phage types among S. Typhimurium will monitor dissemi-
nation of multidrug-resistant strains and strains resistant to
clinically important antimicrobial agents, including
cephalosporins and fluoroquinolones. 
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